Second Messengers as targets for novel drug discovery and development

1988 ◽  
Vol 12 (2) ◽  
pp. 83-83
Author(s):  
Dale B. Evans ◽  
Stan Greenberg
Keyword(s):  
Drug Discovery ◽  
Second Messengers ◽  
Drug Discovery And Development ◽  
Novel Drug

Mechanisms of Anti-retroviral Drug Resistance: Implications for Novel Drug Discovery and Development

2014 ◽  
Vol 13 (5) ◽  
pp. 330-336 ◽  
Author(s):  
Sahra Emamzadeh-Fard ◽  
Shooka Esmaeeli ◽  
Khalilullah Arefi ◽  
Majedeh Moradbeigi ◽  
Behnam Heidari ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Drug Discovery ◽  
Drug Discovery And Development ◽  
Novel Drug

scholarly journals Evaluating Performance of Drug Repurposing Technologies

2020 ◽  
Author(s):  
James Schuler ◽  
Zackary Falls ◽  
William Mangione ◽  
Matthew L. Hudson ◽  
Liana Bruggemann ◽  
...  
Keyword(s):  
Performance Evaluation ◽  
Drug Discovery ◽  
Computational Analysis ◽  
Drug Repurposing ◽  
Evaluation Metrics ◽  
Drug Discovery And Development ◽  
Evaluation Measures ◽  
Cross Platform ◽  
Patient Use ◽  
Novel Drug

AbstractDrug repurposing technologies are growing in number and maturing. However, comparison to each other and to reality is hindered due to lack of consensus with respect to performance evaluation. Such comparability is necessary to determine scientific merit and to ensure that only meaningful predictions from repurposing technologies carry through to further validation and eventual patient use. Here, we review and compare performance evaluation measures for these technologies using version 2 of our shotgun repurposing Computational Analysis of Novel Drug Opportunities (CANDO) platform to illustrate their benefits, drawbacks, and limitations. Understanding and using different performance evaluation metrics ensures robust cross platform comparability, enabling us to continuously strive towards optimal repurposing by decreasing time and cost of drug discovery and development.

scholarly journals Prodrugs from Serendipity to Design by Computational Chemistry Methods

2021 ◽  
Vol 01 (1) ◽  
pp. 6-8
Author(s):  
Rafik Karaman
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Drug Design ◽  
Computational Chemistry ◽  
The Other ◽  
Lead Discovery ◽  
Drug Discovery And Development ◽  
Adme Properties ◽  
Novel Drug ◽  
Complex Organic

Imagination is more important than knowledge when knowledge is limited and cannot solve important questions. Inventiveness in the drug design has been clumsiness in quality and quantity. This may be due to the ineptness and incapability of medicinal chemists to comprehend biochemistry and biology issues. On the other hand, biochemists, biologists, and pharmaceutical chemists do not possess the expertise to make complex organic entities. Hence, a team comprising of all expertise is a must to invoke a novel drug. Drug discovery and development is expensive and time-consuming since it consists of many steps that start with target and lead discovery and end with human clinical trials. The estimation is that about 10-15 years are needed to present a new drug to the market with a cost of 1-1.5 billion dollars (Figure 1), (Karaman 2014 a,b). During the recent few decades, considerable attention has been focused on improving the pharmacokinetics of existing marketed drugs, thus providing new organic entities capable of providing more e!ciency with fewer drawbacks than their corresponding parent drugs. Among the approaches that can fulfill the requirements for invoking therapeutics with optimum absorption, distribution, metabolism, and excretion (ADME) properties is the prodrug approach.

Sign in / Sign up

Export Citation Format

Share Document